Oculus Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ CEO Signature Series

Download as PDF

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences (Nasdaq:OCLS) announced that its CEO and founder, Hoji Alimi, was today's featured guest on the NASDAQ CEO Signature Series webcast hosted by financial reporter, Sasha Salama. In the interview, Mr. Alimi discussed the company's recent milestones including positive results from the U.S. Phase II clinical study of Microcyn(R) Technology in patients with mildly infected diabetic foot ulcers; the approval of Microcyn by China's State Food and Drug Administration (SFDA); and the company's global commercialization efforts.

The webcast can be accessed at http://www.oculusis.com/ceo/ or by visiting Thomson StreetEvents, FactSet CallStreet, vcall.com and InvestorCalendar.com.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores.

The technology has also demonstrated wound healing in chronic and acute wounds in clinical investigational studies. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.

Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Source: Oculus Innovative Sciences, Inc.

Released April 17, 2008